Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BSTGNYSE:CATXNYSE:NVRONASDAQ:TCMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBSTGBiostage$4.45$4.45$4.45▼$4.45$61.78M-1.021,847 shsN/ACATXPerspective Therapeutics$3.17-1.6%$2.47$1.60▼$16.55$235.30M1.091.09 million shs815,918 shsNVRONevro$5.85+0.1%$5.85$3.17▼$10.37$224.32M0.81788,281 shs753,602 shsTCMDTactile Systems Technology$9.84-1.1%$11.52$8.61▼$21.10$228.76M0.94262,227 shs271,092 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBSTGBiostage0.00%0.00%0.00%0.00%0.00%CATXPerspective Therapeutics0.00%-4.52%+31.54%+22.39%-76.17%NVRONevro0.00%0.00%0.00%+0.88%-38.14%TCMDTactile Systems Technology0.00%-1.99%+1.97%-25.23%-17.93%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBSTGBiostageN/AN/AN/AN/AN/AN/AN/AN/ACATXPerspective Therapeutics2.8326 of 5 stars3.63.00.00.03.32.50.0NVRONevro0.1565 of 5 stars1.00.00.00.00.01.70.6TCMDTactile Systems Technology3.7845 of 5 stars3.02.00.00.03.82.53.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBSTGBiostage 0.00N/AN/AN/ACATXPerspective Therapeutics 3.20Buy$12.63298.26% UpsideNVRONevro 1.92Reduce$5.36-8.29% DownsideTCMDTactile Systems Technology 2.00Hold$16.0062.60% UpsideCurrent Analyst Ratings BreakdownLatest BSTG, CATX, TCMD, and NVRO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2025CATXPerspective TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$15.00 ➝ $16.005/14/2025CATXPerspective TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $8.005/13/2025CATXPerspective TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.005/7/2025TCMDTactile Systems TechnologyB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold5/6/2025TCMDTactile Systems TechnologyPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$25.00 ➝ $14.004/7/2025CATXPerspective TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$21.00 ➝ $10.003/31/2025CATXPerspective TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/27/2025CATXPerspective TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$16.00 ➝ $15.003/26/2025CATXPerspective TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.00 ➝ $11.003/19/2025CATXPerspective TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/17/2025CATXPerspective TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.00(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBSTGBiostageN/AN/AN/AN/A($0.26) per shareN/ACATXPerspective Therapeutics$1.43M164.55N/AN/A$2.67 per share1.19NVRONevro$408.52M0.55N/AN/A$8.10 per share0.72TCMDTactile Systems Technology$293.16M0.78$0.69 per share14.21$9.18 per share1.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBSTGBiostage-$6.07M-$0.58N/A∞N/AN/AN/A-174.43%N/ACATXPerspective Therapeutics-$46.51MN/A0.00N/AN/A-4,096.66%-27.40%-23.16%8/11/2025 (Estimated)NVRONevro-$92.21M-$3.05N/AN/AN/A-16.54%-23.52%-10.83%8/4/2025 (Estimated)TCMDTactile Systems Technology$28.51M$0.6614.0611.71N/A5.79%9.37%6.75%8/4/2025 (Estimated)Latest BSTG, CATX, TCMD, and NVRO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2025Q1 2025TCMDTactile Systems Technology-$0.07-$0.13-$0.06-$0.13$63.48 million$61.27 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBSTGBiostageN/AN/AN/AN/AN/ACATXPerspective TherapeuticsN/AN/AN/AN/AN/ANVRONevroN/AN/AN/AN/AN/ATCMDTactile Systems TechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBSTGBiostageN/A2.732.73CATXPerspective TherapeuticsN/A9.609.60NVRONevro0.675.023.76TCMDTactile Systems Technology0.114.363.80Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBSTGBiostageN/ACATXPerspective Therapeutics54.66%NVRONevro95.52%TCMDTactile Systems Technology83.43%Insider OwnershipCompanyInsider OwnershipBSTGBiostage15.30%CATXPerspective Therapeutics3.72%NVRONevro3.20%TCMDTactile Systems Technology2.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBSTGBiostage713.88 million11.76 millionNot OptionableCATXPerspective Therapeutics7074.23 million65.21 millionOptionableNVRONevro1,09038.37 million36.27 millionOptionableTCMDTactile Systems Technology98023.25 million23.36 millionOptionableBSTG, CATX, TCMD, and NVRO HeadlinesRecent News About These CompaniesTwo Sigma Investments LP Sells 31,793 Shares of Tactile Systems Technology, Inc. (NASDAQ:TCMD)June 9, 2025 | marketbeat.comBank of America Corp DE Raises Stake in Tactile Systems Technology, Inc. (NASDAQ:TCMD)June 4, 2025 | marketbeat.comNew Data Demonstrates Significant Clinical and Quality-of-Life Benefits of Flexitouch® Plus in Treating Lymphedema Among Head and Neck Cancer SurvivorsJune 3, 2025 | globenewswire.comMillennium Management LLC Buys New Shares in Tactile Systems Technology, Inc. (NASDAQ:TCMD)June 1, 2025 | marketbeat.comTactile Systems Technology, Inc. (NASDAQ:TCMD) Shares Sold by Nuveen Asset Management LLCMay 29, 2025 | marketbeat.comBNP Paribas Financial Markets Sells 26,955 Shares of Tactile Systems Technology, Inc. (NASDAQ:TCMD)May 29, 2025 | marketbeat.comTactile Systems Technology, Inc. (NASDAQ:TCMD) Shares Bought by Tidal Investments LLCMay 27, 2025 | marketbeat.comMan Group plc Invests $579,000 in Tactile Systems Technology, Inc. (NASDAQ:TCMD)May 27, 2025 | marketbeat.comTactile Systems Technology, Inc. (NASDAQ:TCMD) Stock Position Lessened by D. E. Shaw & Co. Inc.May 26, 2025 | marketbeat.comAmeriprise Financial Inc. Sells 37,472 Shares of Tactile Systems Technology, Inc. (NASDAQ:TCMD)May 26, 2025 | marketbeat.comJane Street Group LLC Purchases 34,846 Shares of Tactile Systems Technology, Inc. (NASDAQ:TCMD)May 25, 2025 | marketbeat.comTactile Medical to Present at Upcoming Investor Conferences in JuneMay 20, 2025 | globenewswire.comDeutsche Bank AG Decreases Stake in Tactile Systems Technology, Inc. (NASDAQ:TCMD)May 19, 2025 | marketbeat.comTactile Systems Technology, Inc. (NASDAQ:TCMD) CFO Sells $29,034.74 in StockMay 15, 2025 | insidertrades.comTactile Systems Technology's (NASDAQ:TCMD) Soft Earnings Don't Show The Whole PictureMay 13, 2025 | finance.yahoo.comTactile Systems Technology, Inc. (NASDAQ:TCMD) Director Sells $31,911.00 in StockMay 10, 2025 | insidertrades.comPiper Sandler Downgrades Tactile Systems Technology (TCMD)May 8, 2025 | msn.comAnalysts Have Been Trimming Their Tactile Systems Technology, Inc. (NASDAQ:TCMD) Price Target After Its Latest ReportMay 7, 2025 | finance.yahoo.comWhy Tactile Systems Technology, Inc.’s (TCMD) Stock Is Down 33.21%May 6, 2025 | aaii.comTactile Systems stock tumbles after Q1 missMay 6, 2025 | investing.comTactile Systems downgraded to Neutral from Overweight at Piper SandlerMay 6, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBSTG, CATX, TCMD, and NVRO Company DescriptionsBiostage OTCMKTS:BSTG$4.45 0.00 (0.00%) As of 07/24/2023Biostage, Inc., a biotechnology company, offers products to cure patients of cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The company's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs, as well as product candidates to treat cancer, injury, and birth defects of the bronchus. Its lead product candidate is Biostage Esophageal Implant for the treatment of severe esophageal disease. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2009 and is headquartered in Holliston, Massachusetts.Perspective Therapeutics NYSE:CATX$3.17 -0.05 (-1.55%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$3.26 +0.10 (+3.00%) As of 06/13/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.Nevro NYSE:NVRO$5.85 +0.01 (+0.10%) Closing price 04/2/2025Extended Trading$5.85 0.00 (0.00%) As of 04/2/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.Tactile Systems Technology NASDAQ:TCMD$9.84 -0.11 (-1.11%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$9.86 +0.02 (+0.15%) As of 06/13/2025 05:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers. The company also provides Kylee, a mobile application to help patients learn about lymphedema, track their symptoms, and treatment, as well as to share their progress with their doctor; and AffloVest, a portable high frequency chest wall oscillation vest to treat patients with retained pulmonary secretions resulting from bronchiectasis, cystic fibrosis, and various neuromuscular disorders. Tactile Systems Technology, Inc. was incorporated in 1995 and is headquartered in Minneapolis, Minnesota. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
